Concepts (261)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 15 | 2020 | 131 | 4.360 |
Why?
|
| Vitamin D Deficiency | 8 | 2019 | 41 | 1.940 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 131 | 1.570 |
Why?
|
| Receptors, Calcitriol | 5 | 2022 | 33 | 1.320 |
Why?
|
| Vitamins | 6 | 2019 | 74 | 1.090 |
Why?
|
| Isothiocyanates | 3 | 2020 | 14 | 1.030 |
Why?
|
| Iron | 7 | 2012 | 136 | 1.030 |
Why?
|
| Dietary Supplements | 8 | 2019 | 222 | 0.970 |
Why?
|
| Sulfoxides | 3 | 2020 | 16 | 0.920 |
Why?
|
| Histone Deacetylases | 3 | 2020 | 61 | 0.890 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 1118 | 0.770 |
Why?
|
| Enterocytes | 3 | 2008 | 24 | 0.700 |
Why?
|
| Nutritional Status | 5 | 2019 | 92 | 0.680 |
Why?
|
| Calcitriol | 4 | 2008 | 24 | 0.640 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 215 | 0.610 |
Why?
|
| Diet, Carbohydrate-Restricted | 2 | 2009 | 9 | 0.590 |
Why?
|
| Caco-2 Cells | 5 | 2020 | 66 | 0.560 |
Why?
|
| RNA, Messenger | 4 | 2008 | 1465 | 0.500 |
Why?
|
| Pregnancy Outcome | 3 | 2013 | 181 | 0.430 |
Why?
|
| TRPV Cation Channels | 2 | 2020 | 18 | 0.430 |
Why?
|
| Bronchiolitis, Viral | 1 | 2012 | 4 | 0.410 |
Why?
|
| Intestinal Absorption | 3 | 2018 | 29 | 0.390 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 34 | 0.390 |
Why?
|
| Iron, Dietary | 4 | 2007 | 9 | 0.380 |
Why?
|
| Ferritins | 6 | 2012 | 30 | 0.380 |
Why?
|
| Obesity | 5 | 2018 | 1166 | 0.370 |
Why?
|
| Diet, Reducing | 1 | 2011 | 27 | 0.370 |
Why?
|
| Humans | 34 | 2022 | 59366 | 0.360 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 138 | 0.350 |
Why?
|
| Vascular Diseases | 1 | 2011 | 75 | 0.350 |
Why?
|
| Bone Density Conservation Agents | 2 | 2009 | 44 | 0.340 |
Why?
|
| Diet | 3 | 2007 | 496 | 0.340 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2009 | 5 | 0.330 |
Why?
|
| Manganese | 1 | 2009 | 24 | 0.320 |
Why?
|
| Fetal Development | 1 | 2009 | 16 | 0.320 |
Why?
|
| Trace Elements | 1 | 2009 | 18 | 0.320 |
Why?
|
| Glycemic Index | 1 | 2009 | 22 | 0.320 |
Why?
|
| Birth Weight | 1 | 2009 | 81 | 0.310 |
Why?
|
| Gene Expression | 2 | 2019 | 809 | 0.310 |
Why?
|
| Infant, Newborn | 4 | 2022 | 1283 | 0.290 |
Why?
|
| Female | 20 | 2022 | 30719 | 0.280 |
Why?
|
| Adipogenesis | 1 | 2008 | 71 | 0.270 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 64 | 0.270 |
Why?
|
| Vitamin D3 24-Hydroxylase | 3 | 2020 | 7 | 0.270 |
Why?
|
| Diet, High-Fat | 2 | 2018 | 163 | 0.270 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 34 | 0.270 |
Why?
|
| Lipoproteins | 1 | 2006 | 80 | 0.260 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2005 | 25 | 0.260 |
Why?
|
| Insulin Resistance | 1 | 2009 | 392 | 0.250 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 203 | 0.240 |
Why?
|
| Pregnancy | 4 | 2022 | 2213 | 0.240 |
Why?
|
| Heart Diseases | 2 | 2004 | 206 | 0.230 |
Why?
|
| Calcium Channels | 2 | 2020 | 101 | 0.230 |
Why?
|
| Weight Loss | 1 | 2006 | 263 | 0.230 |
Why?
|
| Vitamin K 1 | 1 | 2003 | 2 | 0.220 |
Why?
|
| Deficiency Diseases | 1 | 2003 | 12 | 0.210 |
Why?
|
| Minerals | 1 | 2003 | 18 | 0.210 |
Why?
|
| Micronutrients | 1 | 2003 | 18 | 0.210 |
Why?
|
| Calcium, Dietary | 1 | 2002 | 29 | 0.200 |
Why?
|
| Hypertension | 1 | 2008 | 568 | 0.200 |
Why?
|
| Biological Availability | 5 | 2018 | 195 | 0.200 |
Why?
|
| Hemochromatosis | 1 | 2002 | 6 | 0.200 |
Why?
|
| Iron-Binding Proteins | 1 | 2002 | 8 | 0.200 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2002 | 4 | 0.200 |
Why?
|
| Arabs | 1 | 2022 | 6 | 0.200 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 19 | 0.190 |
Why?
|
| Risk Factors | 7 | 2013 | 4986 | 0.190 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 185 | 0.180 |
Why?
|
| Colorectal Neoplasms | 3 | 2011 | 263 | 0.180 |
Why?
|
| Aging | 2 | 2003 | 710 | 0.180 |
Why?
|
| Hydroxamic Acids | 1 | 2020 | 26 | 0.180 |
Why?
|
| Acetylation | 1 | 2020 | 112 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 474 | 0.170 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 13 | 0.160 |
Why?
|
| RNA-Binding Proteins | 1 | 2002 | 386 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 55 | 0.150 |
Why?
|
| Membrane Proteins | 2 | 2017 | 850 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 628 | 0.150 |
Why?
|
| Beverages | 2 | 2013 | 66 | 0.150 |
Why?
|
| Odds Ratio | 2 | 2019 | 747 | 0.150 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 43 | 0.150 |
Why?
|
| Peptides | 2 | 2017 | 549 | 0.140 |
Why?
|
| Animals | 10 | 2018 | 19649 | 0.140 |
Why?
|
| Paneth Cells | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 53 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2022 | 3067 | 0.130 |
Why?
|
| Male | 16 | 2018 | 27742 | 0.130 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 153 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2380 | 0.120 |
Why?
|
| alpha-Tocopherol | 2 | 2012 | 18 | 0.120 |
Why?
|
| Receptors, Transferrin | 2 | 2004 | 33 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 312 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 588 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2006 | 159 | 0.110 |
Why?
|
| beta Carotene | 2 | 2012 | 64 | 0.110 |
Why?
|
| Inflammation | 2 | 2017 | 1098 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 527 | 0.110 |
Why?
|
| Adenoma | 2 | 2011 | 64 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 200 | 0.110 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 584 | 0.110 |
Why?
|
| Malus | 1 | 2013 | 3 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 635 | 0.110 |
Why?
|
| United States | 2 | 2019 | 7426 | 0.100 |
Why?
|
| Catechin | 1 | 2013 | 32 | 0.100 |
Why?
|
| Cytokines | 1 | 2017 | 915 | 0.100 |
Why?
|
| Flavonoids | 1 | 2013 | 73 | 0.100 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2012 | 17 | 0.100 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 5 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 69 | 0.100 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 84 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 2 | 2009 | 56 | 0.090 |
Why?
|
| Vascular Stiffness | 1 | 2011 | 13 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2013 | 163 | 0.090 |
Why?
|
| Steroid Hydroxylases | 2 | 2008 | 9 | 0.090 |
Why?
|
| Prenatal Care | 1 | 2013 | 170 | 0.090 |
Why?
|
| Aged | 8 | 2013 | 13405 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2013 | 461 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 130 | 0.090 |
Why?
|
| Prevalence | 2 | 2011 | 1253 | 0.080 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 6 | 0.080 |
Why?
|
| Comorbidity | 1 | 2013 | 1078 | 0.080 |
Why?
|
| Incidence | 1 | 2013 | 1238 | 0.080 |
Why?
|
| Pneumonia, Viral | 1 | 2012 | 205 | 0.080 |
Why?
|
| Sunlight | 1 | 2009 | 29 | 0.080 |
Why?
|
| Area Under Curve | 2 | 2013 | 141 | 0.080 |
Why?
|
| Homeostasis | 1 | 2011 | 346 | 0.080 |
Why?
|
| Bone Density | 1 | 2009 | 129 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 1552 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2008 | 33 | 0.070 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2008 | 6 | 0.070 |
Why?
|
| Energy Intake | 1 | 2009 | 167 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2008 | 13 | 0.070 |
Why?
|
| Benzoquinones | 1 | 2008 | 14 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 339 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2008 | 21 | 0.070 |
Why?
|
| Meat | 2 | 2011 | 33 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 64 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 25 | 0.070 |
Why?
|
| 3T3-L1 Cells | 1 | 2008 | 83 | 0.070 |
Why?
|
| beta Catenin | 2 | 2018 | 86 | 0.070 |
Why?
|
| Food, Fortified | 2 | 2009 | 18 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 72 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 49 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 71 | 0.070 |
Why?
|
| Dietary Carbohydrates | 1 | 2006 | 58 | 0.070 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 102 | 0.070 |
Why?
|
| Middle Aged | 8 | 2017 | 16310 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 495 | 0.070 |
Why?
|
| Dactinomycin | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2005 | 22 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 442 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 347 | 0.060 |
Why?
|
| Mass Screening | 1 | 2011 | 648 | 0.060 |
Why?
|
| Mice | 4 | 2018 | 10294 | 0.060 |
Why?
|
| Cholesterol | 1 | 2006 | 252 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2007 | 5119 | 0.060 |
Why?
|
| Triglycerides | 1 | 2006 | 231 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 146 | 0.060 |
Why?
|
| Hydroxyl Radical | 1 | 2004 | 6 | 0.060 |
Why?
|
| Preconception Care | 1 | 2004 | 23 | 0.060 |
Why?
|
| Superoxides | 1 | 2004 | 69 | 0.060 |
Why?
|
| 1-Carboxyglutamic Acid | 1 | 2003 | 1 | 0.050 |
Why?
|
| Prothrombin | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2004 | 133 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 302 | 0.050 |
Why?
|
| Protein Binding | 1 | 2008 | 1555 | 0.050 |
Why?
|
| Anemia | 1 | 2004 | 119 | 0.050 |
Why?
|
| Tablets | 1 | 2003 | 16 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 2 | 2018 | 77 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 805 | 0.050 |
Why?
|
| Permeability | 1 | 2003 | 49 | 0.050 |
Why?
|
| Calcium Carbonate | 1 | 2002 | 4 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 244 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 294 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2002 | 39 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2006 | 831 | 0.050 |
Why?
|
| Edible Grain | 1 | 2002 | 27 | 0.050 |
Why?
|
| Fasting | 1 | 2002 | 48 | 0.050 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2002 | 4 | 0.050 |
Why?
|
| Biomarkers | 2 | 2007 | 1306 | 0.050 |
Why?
|
| Milk | 1 | 2002 | 39 | 0.050 |
Why?
|
| Citrus | 1 | 2002 | 40 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 46 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 256 | 0.050 |
Why?
|
| Hemochromatosis Protein | 1 | 2002 | 4 | 0.050 |
Why?
|
| Oxidative Stress | 1 | 2004 | 279 | 0.050 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Collagen | 1 | 2002 | 115 | 0.050 |
Why?
|
| Fruit | 1 | 2002 | 104 | 0.050 |
Why?
|
| Food | 1 | 2002 | 76 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 326 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2002 | 61 | 0.050 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 857 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 297 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 135 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2002 | 305 | 0.040 |
Why?
|
| Massachusetts | 2 | 2007 | 2019 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2013 | 715 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 718 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3231 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 288 | 0.040 |
Why?
|
| Transferrin | 2 | 2012 | 67 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 555 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1189 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 795 | 0.040 |
Why?
|
| Enteritis | 1 | 2018 | 13 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 730 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 297 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2008 | 2903 | 0.040 |
Why?
|
| Axin Protein | 1 | 2017 | 10 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2017 | 19 | 0.040 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 40 | 0.030 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2017 | 11 | 0.030 |
Why?
|
| Muramidase | 1 | 2017 | 46 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 2375 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 71 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1051 | 0.030 |
Why?
|
| Adult | 4 | 2012 | 15679 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 213 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 140 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 152 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 583 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 309 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 258 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 847 | 0.030 |
Why?
|
| Emulsions | 1 | 2018 | 457 | 0.030 |
Why?
|
| Mutation | 1 | 2002 | 2456 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 941 | 0.030 |
Why?
|
| Finland | 1 | 2012 | 19 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2092 | 0.030 |
Why?
|
| Placebos | 1 | 2012 | 68 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2013 | 146 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 67 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 17 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 284 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 57 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 4273 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 805 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 5835 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 617 | 0.020 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2009 | 6 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 439 | 0.020 |
Why?
|
| Brazil | 1 | 2009 | 88 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2007 | 20 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2007 | 14 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2007 | 10 | 0.020 |
Why?
|
| Carcinogens | 1 | 2007 | 37 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2338 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 193 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 451 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2006 | 254 | 0.010 |
Why?
|
| China | 1 | 2004 | 134 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 902 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 1235 | 0.010 |
Why?
|
| Cebidae | 1 | 2002 | 1 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2012 | 5281 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2012 | 6069 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2053 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 1925 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2516 | 0.010 |
Why?
|